Profile data is unavailable for this security.
About the company
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
- Revenue in USD (TTM)0.00
- Net income in USD-25.17m
- Incorporated2015
- Employees18.00
- LocationMoleculin Biotech Inc5300 Memorial Dr Ste 950HOUSTON 77007-8274United StatesUSA
- Phone+1 (713) 300-5160
- Fax+1 (302) 636-5454
- Websitehttps://moleculin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | 0.00 | -7.39m | 6.57m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.70m | 7.00 | -- | 2.12 | -- | 171.28 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.72m | 4.00 | -- | 1.05 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -25.17m | 6.74m | 18.00 | -- | 0.3428 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 6.93m | 8.00 | -- | -- | -- | 42.75 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.96m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 6.97m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 7.08m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 7.09m | 75.00 | 0.0003 | 0.00002 | 1.31 | 0.3985 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -137.05m | 7.19m | 16.00 | -- | -- | -- | 31.83 | -5.53 | -5.53 | 0.0102 | 0.241 | 0.0092 | -- | 12.91 | 14,125.00 | -557.63 | -63.43 | -896.39 | -85.72 | -- | -- | -60,641.15 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.21m | 7.24m | 3.00 | -- | -- | -- | -- | -0.1674 | -0.1674 | 0.00 | -0.8904 | 0.00 | -- | -- | 0.00 | -634.64 | -- | -- | -- | -- | -- | -- | -- | -- | -14.05 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.18m | -2.21m | 7.26m | 30.00 | -- | 0.7474 | -- | 0.7901 | -0.1108 | -0.1108 | 0.5807 | 0.5403 | 0.9647 | 7.19 | 5.77 | -- | -23.17 | -3.83 | -27.98 | -5.02 | 13.88 | 14.55 | -24.02 | -3.04 | 4.87 | -118.92 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| NuCana PLC (ADR) | 0.00 | -37.54m | 7.29m | 25.00 | -- | 1.44 | -- | -- | -234.80 | -234.80 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -91.91 | -41.01 | -177.64 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0689 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 7.30m | 389.00 | 0.0013 | 0.0001 | 0.7915 | 0.1282 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Exicure Inc | 500.00k | -8.17m | 7.32m | 5.00 | -- | 4.54 | -- | 14.64 | -4.72 | -4.72 | 0.2889 | 0.9323 | 0.0354 | -- | -- | 83,333.34 | -57.87 | -41.52 | -69.90 | -55.78 | -- | -- | -1,634.40 | -290.95 | -- | -- | 0.3827 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Moleculin Biotech Inc's reporting currency: US Dollar USD
11.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 156.00k | 5.48% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 83.80k | 2.95% |
| LPL Financial LLCas of 30 Jun 2024 | 33.75k | 1.19% |
| Geode Capital Management LLCas of 30 Jun 2024 | 19.76k | 0.70% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 12.48k | 0.44% |
| Atticus Wealth Management LLCas of 30 Jun 2024 | 3.33k | 0.12% |
| Tower Research Capital LLCas of 30 Jun 2024 | 2.00k | 0.07% |
| Newbridge Financial Services Group, Inc.as of 30 Jun 2024 | 1.37k | 0.05% |
| Vanguard Global Advisers LLCas of 30 Jun 2024 | 621.00 | 0.02% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 400.00 | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
